二次性脳卒中予防のための抗血小板薬と抗凝固薬の組み合わせによる出血リスク: 傾向スコアマッチ分析
Salia Farrokh1,2, Krishna Nalleballe3, Sanjeeva Onteddu3
1Division of Neurosciences Critical Care, Department of Anesthesiology and Critical Care Medicine, Neurology, and Neurosurgery Johns Hopkins University School of Medicine Baltimore MD USA.
Journal of the American Heart Association
|August 20, 2025
まとめ
抗血小板薬と抗凝固剤を併用すると,脳卒中患者の長期的な出血リスク,特に12ヶ月以上の脳内出血のリスクが増加します. 胃腸出血のリスクは,これらの併用療法で急性および長期的に上昇します.
科学分野:
- 心臓病科
- 神経学
- 薬理学について
背景:
- 急性不全性脳卒中 (AIS) の二次性脳卒中予防のための抗血小板薬と抗凝固薬の併用の安全性に関するデータは限られている.
- 動脈動と急性心筋梗塞を併発した患者の場合,これらの組み合わせに関連した出血リスクは十分に確立されていません.
研究 の 目的:
- シングル (SAPT) またはダブル抗血小板療法 (DAPT) と抗凝固剤を併用した出血リスクを調べる.
- AIS,心房細動,急性心筋梗塞の患者にこのリスクを比較する.
主な方法:
- 76の米国の病院からのTrinetXデータを用いた遡及的横断コホート研究.
- 抗凝固剤のみ,抗凝固剤とSAPT,および抗凝固剤とDAPTのサブコホートを比較した傾向スコアマッチ分析.
- 急性自発性脳内出血および胃腸出血のリスクの評価 3ヶ月,12ヶ月,および追跡期間中.
主要な成果:
- 144, 434人の患者のうち,8772人が抗凝固剤のみ,88, 430人が抗凝固剤とSAPTを併用し,47, 232人が抗凝固剤とDAPTを併用した.
- 抗凝固剤単独投与と比較して,3ヶ月と12ヶ月で脳内出血のリスクが有意に増加しなかった.
- 長期にわたる脳内出血リスクの上昇 (SAPTではOR1. 26; DAPTではOR1. 34) 胃腸出血リスクの上昇
結論:
- AIS後に抗血小板薬と抗凝固剤を併用すると,特に12ヶ月を超えて,長期にわたる脳内出血のリスクが増加する可能性があります.
- 併用療法では,急性および長期的な胃腸出血のリスクが増加します.
- これらの発見を確認するには,より大きな前向きな研究が必要である.
関連する概念動画
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Venous Thrombosis IV: Nursing Management
23
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
23
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K


